Pizzocaro G, Piva L, Faustini M, Mangiarotti B, Nicolai N, Salvioni R, Milani A, Zanoni F
Divisione di Oncologia Urologica, Istituto Nazionale Tumori, Milano.
Arch Ital Urol Androl. 1993 Apr;65(2):177-80.
From January 1987 to December 1990, 14 consecutive patients with resectable metastases from renal cell carcinoma, underwent 3 cycles of preoperative alpha-2a Interferon (INF), 18 MUI s.c. 3 times a week, and Vinblastine (VLB), 0.15 mg/kg on day 1, every 21, days. Out of the 13 patients who completed the treatment, 4 (30.7%) achieved a clinical response (1 CR and 3 PR). Nine (69.3%) patients were submitted to surgery: all, including the CRer, had residual cancer and only 4 were radically resected. The latter were further submitted to 3 INF and VLB cycles: 2 relapsed after 7 and respectively 30 months, whilst 2 (15.4%) are alive disease-free at 12 and 52 months respectively.
1987年1月至1990年12月，14例连续的肾细胞癌可切除转移患者接受了3个周期的术前α-2a干扰素（INF）治疗，皮下注射18 MU，每周3次，以及长春碱（VLB）治疗，第1天剂量为0.15 mg/kg，每21天一次。在完成治疗的13例患者中，4例（30.7%）获得临床缓解（1例完全缓解和3例部分缓解）。9例（69.3%）患者接受了手术：所有患者，包括完全缓解者，均有残留癌，只有4例接受了根治性切除。后4例患者又接受了3个周期的INF和VLB治疗：2例分别在7个月和30个月后复发，而2例（15.4%）分别在12个月和52个月时无病存活。
